

(11) Publication number : **0 439 954 A2**

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number : **90314221.4**

(22) Date of filing : **24.12.90**

(51) Int. Cl.⁵ : **C12N 15/62, C12N 15/26,
C12N 15/31, C12N 15/48,
C12N 15/57, A61K 48/00,
C12N 15/16, // C12N15/17,
C12N15/24, C12N15/56,
C12N15/53, C12N15/55**

(30) Priority : **22.12.89 US 456095
14.06.90 US 538276**

(43) Date of publication of application :
07.08.91 Bulletin 91/32

(64) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant : **SERAGEN, INC.
97 South Street
Hopkinton, MA 01748 (US)**

(72) Inventor : **Murphy, John R.
15 Astra
Wayland, Massachusetts 01778 (US)**

(74) Representative : **Deans, Michael John Percy et
al
Lloyd Wise, Tregear & CO. Norman House
105-109 Strand
London WC2R 0AE (GB)**

(54) **Hybrid molecules having translocation region and cell-binding region.**

(57) A hybrid molecule including a first part, a second part and a third part connected by covalent bonds,
(a) the first part including a portion of the binding domain of a cell-binding ligand, which portion is able to cause the hybrid molecule of the invention to bind to an animal cell;
(b) the second part including a portion of a translocation domain of a protein, which portion is capable of translocating the third part across the cytoplasmic membrane of the cell; and
(c) the third part including a chemical entity to be introduced into the cell, provided that (i) the hybrid molecule is produced by expression of a recombinant DNA molecule encoding the hybrid molecule, and (ii) the second and third parts are not segments of the same naturally-occurring polypeptide toxin;
a recombinant DNA molecule encoding the hybrid molecule; and
a method of producing the hybrid molecule.

EP 0 439 954 A2

HYBRID MOLECULES HAVING TRANSLOCATION REGION AND CELL-BINDING REGION

Background of the Invention

This invention relates to hybrid molecules having a cell-binding part and a translocation part.

The literature contains many examples of fused genes which code for hybrid proteins. For example, Villakomaroff et al., Proc. Natl. Acad. Sci. U.S.A. 75 : 3727-3731, 1978, describes a fused gene made up of a eukaryotic structural gene fused to a non-cytoplasmic bacterial gene. The fused gene codes for a hybrid protein which is transported out of the cytoplasm.

Hybrid proteins also have been made by other methods (e.g., the coupling of two different protein molecules) which do not involve recombinant DNA techniques. For example, it has been proposed to form, by coupling, therapeutic hybrid proteins consisting of portions of toxin molecules coupled to a ligand capable of binding specifically to a selected class of cells. One attempt to make such a hybrid protein, reported in Chang et al., J. Biol. Chem. 252 :1515-1522, 1977, resulted in a hybrid consisting of the diphtheria toxin A chain coupled to human placental lactogen hormone by cross-linking through a disulfide bond. Although the hybrid protein bound to cells containing lactogen receptors, it did not inhibit protein synthesis in those cells.

A hybrid protein consisting of the ricin toxin A chain coupled to the β chain of human chorionic gonadotropin hormone by similarly cross-linking through a disulfide bond has also been reported ; although said to have specificity, its binding capacity has not been reported. Furthermore, extremely high concentrations were required to significantly inhibit protein synthesis in rat Leydig tumor cells, making it difficult to distinguish between "non-specific" entry caused by endocytosis and "specific" entry caused by transport of the toxic portion of the hybrid across the cytoplasmic membrane of the target cells (Oeltman et al., J. Biol. Chem. 254 :1028-1032, 1979). The same shortcoming was found in a hybrid protein consisting of diphtheria A coupled to insulin using cystamine as the cross-linking agent (Miskimins et al., Biochem. Biophys. Res. Commun. 91 :143-151, 1979). A hybrid consisting of ricin A coupled to epidermal growth factor (EGF) by means of a heterobifunctional cross-linker has also been made ; the binding characteristics provided by the EGF are not limited to specific cells, but rather encompass a wide variety of cell types (Cawley et al., Cell 22 :563-570, 1980).

As illustrated in Fig. 1, the natural diphtheria toxin molecule consists of several functional "domains" which can be characterized, starting at the amino terminal end of the molecule, as hydrophobic leader signal sequence (amino acids Val₂₅ - Ala₄₁) ; enzymatically-active Fragment A (amino acids Gly₁ - Arg₁₉₃) ; the protease-sensitive disulfide loop I₁ (amino acids Cys₁₈₆ - Cys₂₀₁), containing a cleavage domain ; and Fragment B (amino acids Ser₁₉₄ - Ser₆₃₆), which includes a translocation domain and a generalized binding domain flanking a second disulfide loop (I₂, amino acids Cys₄₈₁ - Cys₄₇₁).

The process by which diphtheria toxin intoxicates sensitive eukaryotic cells involves at least the following steps : (i) the binding domain of diphtheria toxin binds to specific receptors on the surface of a sensitive cell ; (ii) while bound to its receptor, the toxin molecule is internalized into an endocytic vesicle ; (iii) either prior to internalization, or within the endocytic vesicle, the toxin molecule undergoes a proteolytic cleavage in I₁ between fragments A and B ; (iv) as the pH of the endocytic vesicle decreases to below 6, the toxin spontaneously inserts into the endosomal membrane ; (v) once embedded in the membrane, the translocation domain of the toxin facilitates the delivery of Fragment A into the cytosol ; (vi) the catalytic activity of Fragment A (i.e., the nicotinamide adenine dinucleotide - dependent adenosine diphosphate (ADP) ribosylation of the eukaryotic protein synthesis factor termed "Elongation Factor 2") causes the death of the intoxicated cell. It is apparent that a single molecule of Fragment A introduced into the cytosol is sufficient to shut down the cell's protein synthesis machinery and kill the cell. The mechanism of cell killing by *Pseudomonas* exotoxin A, and possibly by certain other naturally-occurring toxins, is very similar.

Summary of the Invention

In general, the invention features, in one aspect, a hybrid molecule including a first part, a second part, and a third part connected by covalent bonds,

(a) the first part including a portion of the binding domain of a cell-binding ligand, which portion is able to cause the hybrid molecule of the invention to bind to an animal cell ;

(b) the second part including a portion of a translocation domain of a protein, which portion is capable of translocating the third part across the cytoplasmic membrane of the cell ; and

(c) the third part including a chemical entity (here, a polypeptide) to be introduced into the cell, provided that (i) the hybrid molecule is produced by expression of a recombinant DNA molecule encoding the hybrid molecule, and (ii) the second and third parts are not segments of the same naturally-occurring polypeptide

toxin, (although the first and second parts may be derived from the same toxin : e.g., diphtheria toxin or *Pseudomonas* exotoxin A). "Translocation" here means the facilitation of movement of a chemical entity from the exterior surface of a cellular membrane (or what constituted the exterior surface prior to formation of an endocytic vesicle), through the membrane, and into the cytosol at the interior of the cell. A "translocation domain" is a segment of a protein which, when the protein is bound to the exterior surface of a cellular membrane, is capable of translocating some portion of that protein through the membrane.

The invention also features a hybrid molecule including a first part, a second part, and a third part connected by covalent bonds,

(a) the first part including a portion of the binding domain of a cell-binding ligand (which may be a polypeptide ligand or may be another type of ligand such as a steroid hormone), which portion is effective to cause the hybrid molecule to bind to a cell of an animal ;

(b) the second part including a portion of a translocation domain of a protein, which portion is capable of translocating the third part across the cytoplasmic membrane of the cell ; and

(c) the third part including a chemical entity (which may or may not be a polypeptide) to be introduced into the cell, provided that (i) the first and second parts are not segments of the same naturally-occurring polypeptide toxin, and (ii) likewise, the second and third parts are not segments of the same naturally-occurring polypeptide toxin.

In preferred embodiments, the second part of either type of hybrid molecule described above comprises at least a portion of the translocation domain of a naturally-occurring toxin (e.g. diphtheria toxin or *Pseudomonas* exotoxin A), and the ligand comprises a hormone (e.g., a polypeptide hormone such as insulin, Interleukin II (also termed "IL2"), Interleukin IV, Interleukin VI or EGF) ; an antigen-binding, single-chain analog of a monoclonal antibody ; or a polypeptide toxin capable of binding to the desired class of cells. Where all three parts are polypeptides, the hybrid molecule is preferably a recombinant protein (that is, a protein produced by recombinant DNA techniques). More preferably, the third part is an antigen-binding, single-chain analog of a monoclonal antibody (where such antigen is, for example, a viral protein such as the human immunodeficiency virus (HIV) protease), or alternatively, the enzymatically active portion of an enzyme (e.g., hexosaminidase A; α -1,4-glucosidase ; phenylalanine hydroxylase ; a protease ; a nuclease ; or a toxin such as cholera toxin, LT toxin, C3 toxin, Shiga toxin, *E. coli* Shiga-like toxin, ricin toxin, pertussis toxin, tetanus toxin, diphtheria toxin or *Pseudomonas* exotoxin A), and most preferably it supplies an enzymatic activity in which the cell is deficient : as, for example, in the case of a genetic deficiency. Where the enzyme is cholera toxin, the resulting hybrid molecule may be used to raise the cyclic AMP level within a target animal cell : preferably, the target cell so treated is a T-cell and the hybrid molecule includes at least a portion of the binding domain of IL2. The hybrid molecule of the invention includes the cholera toxin A/diphtheria toxin B/IL2 hybrid polypeptide encoded by the plasmid illustrated in Fig. 6 ; the Shiga-like toxin A/diphtheria toxin B/IL2 hybrid polypeptide encoded by the plasmid illustrated in Fig. 9 ; the ricin A/diphtheria toxin B/IL2 hybrid polypeptide encoded by the plasmid illustrated in Fig. 12 ; the phenylalanine hydroxylase/diphtheria toxin fragment B hybrid polypeptide encoded by the plasmid illustrated in Fig. 14 ; an HIV protease-binding protein (HIVP-BP)/diphtheria toxin B/IL2 hybrid polypeptide prepared as hereinafter described ; and a Shiga-like toxin A/IL2 hybrid in which both the enzymatic activity and the translocation function are provided by the Shiga-like toxin A portion of the hybrid, and which contains a proteolytically-sensitive disulfide loop. Also included are biologically active mutational analogs of any of the above hybrid polypeptides. As used herein, a "biologically active mutational analog" is a polypeptide which exhibits the same type of cell-binding specificity and the same type of biological activity (e.g., a particular enzymatic or antigen-binding activity) as the listed hybrid polypeptide of which it is an analog, but which differs from such listed hybrid polypeptide by one or more deletions and/or one or more substitutions of segments of one or more amino acid residues. Preferably, the amino acid sequence of the biologically active mutational analog shows at least a 70% (more preferably 80% and most preferably 90%) homology (i.e., identity of amino acid sequence) with the hybrid polypeptide of which it is an analog, and the analog exhibits at least 50% (more preferably, at least 75%) of a biological activity exhibited by the hybrid polypeptide of which it is an analog.

Also within the invention is a recombinant DNA molecule encoding any of the above hybrid polypeptide molecules (including biologically active mutational analogs), a vector including such a recombinant DNA molecule, a cell containing such a vector or recombinant DNA molecule (and which preferably is capable of expressing the recombinant DNA molecule to produce the hybrid polypeptide encoded by it), and a method of preparing the hybrid polypeptide molecule of the invention by permitting a cell containing a recombinant DNA molecule encoding the polypeptide (the "transformed cell") to express the recombinant DNA molecule.

In other preferred embodiments, the third part comprises a detectable label, more preferably a fluorescent moiety, a radioactive moiety, or an electron-dense moiety.

The invention also features a method of labeling a class of cells, which method involves contacting the cells with a hybrid molecule having a third part comprising a detectable label.

Also included in the invention are (1) a method of treating an animal having a deficiency in a certain enzyme, by administering to the animal an effective amount of a hybrid molecule comprising that enzyme ; and (2) a method of treating a human patient infected with HIV, by administering to the patient an effective amount of a hybrid molecule having as its third part an HIV protease-binding, single-chain analog of a monoclonal antibody against HIV protease.

Based upon the observation that certain types of polypeptide toxins have three separate functional regions, one region which binds the molecule to particular receptors on the surface of a target cell, a second one which facilitates entry of the enzymatically-active region into the cytosol of the cell, and a third region which exhibits the enzymatic activity that characterizes the toxic effect of the molecule, the invention includes tripartite hybrid molecules in which any of these regions may be replaced with functionally comparable regions from other sources. That is, the first functional region may be replaced with a particular binding moiety which binds the hybrid molecule to a selected class of cells, such as IL2 (which binds to high-affinity IL2 receptor-bearing T-cells), or α melanocyte stimulating hormone (α MSH, which binds to melanocytes), or a moiety which binds to a broad spectrum of cell types, as is characteristic of the binding domains of cholera toxin and diphtheria toxin ; the second part may be taken from any type of polypeptide in which a translocation domain is identifiable, but will most likely be from a toxin molecule that translocates in a manner similar to diphtheria toxin and *Pseudomonas* exotoxin A. The third part may be any type of moiety that one wants to insert into the cell and that will fit through the channel in the membrane formed by the translocation domain : for example, a cell-killing enzyme such as Shiga toxin ; a metabolic enzyme such as phenylalanine hydroxylase (the enzyme in which phenylketonurics are deficient) ; an antigen-binding, single-chain analog of a monoclonal antibody against an antigen that appears within the target cell ; or a fluorescent label. A proteolytically-sensitive loop (such as I₁ of diphtheria toxin) between the enzymatically-active region of the hybrid and the remainder of the hybrid appears to play an important role in the hybrid's function.

Although the medical community is rapidly expanding its understanding of the molecular bases of many diseases, one problem has particularly frustrated efforts to translate this understanding into rational protocols for treating the diseases : the problem of how to direct the appropriate therapy into the affected cells so that it can function properly to alleviate or cure the disease. By providing such a method, the present invention will have virtually unlimited applications : from treating genetic deficiency diseases by delivering to affected cells an enzyme supplying the missing function, to supplementing cellular levels of a particular enzyme or a scarce precursor or cofactor, to directing toxins or other poisons to destroy particular cells (such as adipocytes, cancer cells, or virus-infected cells), to counteracting viral infections such as HIV (which causes Acquired Immunodeficiency Syndrome ("AIDS")) by introducing into appropriate cells antibodies to viral proteins. The invention also provides a means for getting other, non-therapeutic substances, such as detectable labels, into targeted cells. The use of a translocation mechanism ensures that the hybrid will be effective in relatively low doses, since a high proportion of the substance of interest will be taken into the targeted cells.

To the extent that the three parts of the hybrids of the invention are polypeptides, they may be manufactured as a single hybrid recombinant protein, permitting reproducibility, consistency, and the precise control of composition which is desirable for any pharmaceutical product.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof and from the claims.

Description of the Preferred Embodiments

The drawings will be briefly described.

Drawings

Fig. 1 is a diagrammatic representation of the diphtheria toxin molecule.

Fig. 2 is a restriction map showing the location and orientation of the diphtheria tox gene on the 3.9 kb BamHI restriction fragment of corynephage Φ 24.

Fig. 3 is a representation of the diphtheria toxin gene and flanking regions, with the protein encoded shown above ; the B' region is the region between the labeled Sau3A1-2 and SphI sites.

Fig. 4 is a diagrammatic representation of the strategy used to construct a plasmid encoding fragment B' of diphtheria toxin.

Fig. 5 is a representation of the nucleotide sequence of the Vibrio cholerae toxin gene, with amino acids shown below corresponding codons.

Fig. 6 is a diagrammatic representation of the cloning strategy followed to construct a plasmid encoding cholera toxin A₁-diphtheria toxin B'- IL2 hybrid.

Fig. 7 is a diagrammatic representation of the cloning strategy followed in order to construct the plasmid pPA123.

Fig. 8 is a representation of the nucleotide sequence of the *E. coli* bacteriophage H19B Shiga-like toxin gene, with amino acids shown below corresponding codons.

Fig. 9 is a diagrammatic representation of a cloning strategy proposed for constructing a plasmid encoding a Shiga-like toxin A-diphtheria toxin B'-IL2 hybrid.

Fig. 10 is a diagrammatic representation of an alternative cloning strategy for constructing a plasmid encoding a Shiga-like toxin A-diphtheria toxin B'-IL2 hybrid.

Fig. 11 is a representation of the nucleotide sequence of the *Ricinus communis* ricin gene, with amino acids shown above corresponding codons; this figure is adapted from Fig. 2 of Halling et al. (Nucl. Acids Res. 13:8019-8033, 1985).

Fig. 12 is a diagrammatic representation of the cloning strategy proposed for constructing a plasmid encoding a ricin A-diphtheria toxin B'-IL2 hybrid.

Fig. 13 is a representation of the nucleotide sequence of human phenylalanine hydroxylase cDNA, with amino acids shown below corresponding codons.

Fig. 14 is a diagrammatic representation of a cloning strategy proposed for constructing a plasmid encoding a phenylalanine hydroxylase-diphtheria toxin B hybrid.

Structure

One embodiment of the hybrid molecule of the invention is a three-part hybrid protein which includes (1) a cell-binding domain; (2) a translocation domain, such as that of diphtheria toxin; and (3) a polypeptide to be introduced into the cell, which polypeptide is not derived from the same naturally-occurring protein as is the translocation domain sequence. The cell-binding domain may be generalized (i.e., it is capable of binding the hybrid molecule to a wide variety of cell types, like the cell-binding domain of naturally-occurring diphtheria toxin), or specific for one or a few types of cells. The third part of the hybrid is covalently linked to the translocation domain, such that the translocation domain is capable of translocating the third part into or across the membrane of the cell to which the cell-binding portion of the hybrid is bound. This third part may be, for example, an enzymatically active polypeptide, an antigen-binding portion of a monoclonal antibody, or a detectable label such as a fluorescent dye. It may not, however, be a fragment of the same naturally-occurring molecule from which the translocation domain originates.

Naturally-occurring proteins which are known to have a translocation domain include diphtheria toxin and *Pseudomonas* exotoxin A, and may include other toxins and non-toxin molecules, as well. The translocation domains of diphtheria toxin and *Pseudomonas* exotoxin A are well characterized (see, e.g., Hoch et al., Proc. Natl. Acad. Sci. USA 82:1692-1696, 1985; Colombatti et al., J. Biol. Chem. 261:3030-3035, 1986; and Deleers et al., FEBS 160:82-86, 1983), and the existence and location of such a domain in other molecules may be determined by methods such as those employed by Hwang et al., Cell 48:129-136, 1987; and Gray et al., Proc. Natl. Acad. Sci. USA 81:2645-2649, 1984.

The segment of diphtheria toxin labelled "Fragment B" in Fig. 3 includes both the translocation domain and the generalized cell-binding domain of the naturally-occurring molecule. Truncation of Fragment B to the segment marked B' effectively eliminates the cell-binding function of diphtheria toxin while retaining the translocation function of the molecule. A portion of Fragment B encoded by a sequence ending at or downstream from the *Sph*1 restriction site may be used for the translocation domain; however, if the hybrid includes a cell-binding region other than that of diphtheria toxin, the portion of Fragment B downstream from the *Sph*1 site may be included only if it does not include sequences encoding a sufficient part of the diphtheria toxin receptor-binding domain to yield a functional diphtheria toxin receptor-binding domain.

The part of the hybrid protein contributed by the polypeptide ligand can consist of the entire ligand, or a portion of the ligand which includes the entire binding domain of the ligand, or an effective portion of the binding domain. When the ligand being used is large, it is desirable that as little of the non-binding portion as possible of the ligand be included, so that the binding domain of the molecule is positioned close to the translocation domain. It is also desirable to include all or most of the binding domain of the ligand molecule.

The polypeptide portions of the hybrids of the invention are conveniently made using recombinant DNA techniques involving forming the desired fused gene encoding the hybrid protein, and then expressing the fused gene. Chemical cross-linking is utilized only where one or more of the parts of the hybrid molecule are not polypeptides.

Standard procedures for DNA cloning, cell transformation and plasmid isolation (as described, for example, by Maniatis et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982), and for oligodeoxynucleotide synthesis, could be employed to carry out the following construc-

1. *Introduction*

1

1

10

1

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

After insertion into the plane of the membrane of the endocytic vesicle, the labeled hybrid protein can "traf-

fic", as follows. The endocytic vesicle buds off from the cytoplasmic membrane and enters the cytoplasm of the cell, where it can merge with a lysosome into which the labeled hybrid protein is then incorporated. Alternatively, the endocytic vesicle can recycle to the cytoplasmic membrane of the cell. In either case, the label remains trapped in the target cell.

As is mentioned above, a major diagnostic use of the labeled hybrid proteins will be the *in vivo* and *in vitro* detection of metastatic loci, using conventional cell staining and labeling techniques. Such detection could be of particular value in surgery, by providing the surgeon with information needed to know how much tissue to excise when removing, e.g., metastatic melanoma cells.

Example 2. Construction of a cholera toxin A₁-diphtheria toxin B'-IL2 gene, and use of the resultant hybrid protein

Plasmid pCVD2 containing the coding sequence for the enzymatically-active A₁ fragment of cholera toxin (see Fig. 5) was prepared from a *Vibrio cholera* DNA library as described by Mekalanos et al. (Nature 306 :551-557, 1983). Fig. 6 outlines the strategy employed in engineering a cholera toxin A₁-diphtheria toxin B'-IL2 gene. Briefly, pCVD2 was cleaved with the restriction enzyme XbaI at the unique XbaI site. The following synthetic linker, which has 1/2 of an XbaI site at each end, was ligated to the linearized plasmid in order to introduce a NcoI site upstream from the XbaI site :

```

5' C TAG ACC ATG GGA AAT GAT GAT AAG TTA-
3'      TGG TAC CCT TTA CTA CTA TTC AAT-
peptide: fmet-Gly-Asn-Asp-Asp-Lys-Leu-
          1/2
          XbaI

```

```

(cont.) - TAT CGG GCA GAT T - 3'
        - ATA GCC CGT CTA AGA TC - 5'
        - Tyr-Arg-Ala-Asp-Ser-Arg
          1/2
          XbaI

```

The appropriate construct was selected by restriction site mapping and sequence determinations, and then was digested with NcoI and ClaI to produce a NcoI-ClaI fragment. This in turn was digested with ScrFI. The 3' end of the resulting NcoI-ScrFI fragment was ligated to the following synthetic linker :

```

5' - G GGT TCA GGG CC - 3'
3' - CCA AGT C - 5'
peptide: Pro-Gly-Ser-Gly-Pro
          1/2          1/2
          ScrFI       ApaI

```

The polypeptide encoded by the resulting NcoI-ApaI fragment lacks the natural cholera toxin signal sequence, having instead fmet-Gly followed by the mature A₁ region of cholera toxin, followed by Gly-Ser-Gly-Pro. This construct can be cloned into a plasmid that encodes diphtheria toxin fragment B' fused to the human interleukin-2 gene (plasmid pPA123, Fig. 7). Plasmid pPA123 was constructed from plasmid pDW124 (Diane Williams, Ph.D. dissertation, Boston University School of Medicine, Department of Microbiology, Boston, MA, 02118, 1989) as outlined in Fig. 7. Plasmid pDW124 encodes a diphtheria toxin fragment A-fragment B'-IL2 fusion protein that is expressed off the *trc* promoter in *E. coli*. The sequences encoding fragment A were deleted by digestion with the restriction endonucleases NcoI and NsiI. The following oligonucleotides were used to rebuild the fragment A/B disulfide loop (I₁) sequence, introduce an ApaI site on the 5' end of the loop, and recreate the NcoI site encoding the translation-initiating ATG codon :

5' - C ATG GGG TCA GAT GGG CCC TGT GCA GGA AAT CGT GTC-
 3' - CC AGT CTA CCC GGG ACA CGT CCT TTA GCA CAG-
 5 peptide: fmet-Gly-Ser-Val-Gly-Pro-Cys-Ala-Gly-Asn-Arg-Val-
 1/2 ApaI
 NcoI

10 (cont.) -AGG CGA TCA GTA GGT AGC TCA TTG TCA TGC A - 3'
 -TCC GCT AGT CAT CCA TCG AGT AAC AGT - 5'
 -Arg-Arg-Ser-Val-Gly-Ser-Ser-Leu-Ser-Cys
 Sau3AI 1/2
 NsiI

15 Plasmid pPA123 resulted from ligating the above oligonucleotide fragment onto the NcoI-NsiI-digested pDW124 vector fragment. Plasmid pPA123 can now be used to fuse sequences encoding cholera toxin fragment A₁ to diphtheria toxin B'-IL2 as shown in Fig. 6. Plasmid pPA123 is digested with restriction enzymes NcoI and ApaI, and the resulting vector fragment is ligated to the modified cholera toxin fragment A₁ described above, to yield a plasmid encoding a cholera toxin A₁-diphtheria toxin B'-IL2 hybrid ("CTA/DTB'/IL2 hybrid"), which is expressed from the *trc* promoter on the plasmid.

20 Following expression of the recombinant gene in E. coli, the CTA/DTB'/IL2 hybrid protein can be isolated and used in appropriate treatment regimens: for example, as an adjunct to treatment with diphtheria toxin-IL2 hybrid. Diphtheria toxin-IL2 hybrid effectively targets the cell-killing ability of diphtheria toxin to cells bearing the IL2 receptor, such as certain leukemic T-cells. However, the pharmacological effectiveness of diphtheria toxin-IL2 hybrid is diluted by circulating endogenous IL2, which is naturally synthesized by activated T-cells and which competes with diphtheria toxin-IL2 hybrid for IL2 receptors on T-cells. By first exposing the target cells to CTA/DTB'/IL2 hybrid, the biological activity of cholera toxin can be harnessed to alleviate this problem. The A₁ subunit of natural cholera toxin enzymatically catalyzes the ADP-ribosylation of a GTP-binding regulatory component of the adenylate cyclase complex, resulting in the accumulation of cyclic AMP within the affected cell and thereby disrupting a multitude of cellular functions without killing the cell. Targeting the cholera toxin A₁ activity specifically to cells bearing the IL2 receptor will result in the temporary inhibition of IL2 synthesis within those cells. This permits depletion of the amount of circulating IL2 available to compete with diphtheria toxin-IL2 for IL2 receptors, without interfering with expression of IL2 receptors on the surfaces of the T-cells and without injuring non-targeted cells. Subsequent treatment with diphtheria toxin-IL2 will thus be more effective at killing T-cells than if CTA/DTB'/IL2 hybrid had not been used.

Example 3. Construction of a Shiga-like toxin A-diphtheria toxin B'-IL2 gene, and use of the resultant hybrid protein

40 The DNA sequence and corresponding amino acid sequence for the A subunit of Shiga-like toxin ("SLT-A") are shown in Fig. 8. Bacteriophage H19B DNA from a strain of E. coli that produces SLT-A is prepared as described by Calderwood et al. (Proc. Natl. Acad. Sci. USA 84 :4364-4368, 1987) and digested with TaqI and XmnI. A TaqI-XmnI fragment (approx. 650 bp) corresponding to most of the coding sequence for SLT-A (the "sltA gene") is isolated therefrom (see Fig. 9); the following oligonucleotide is then ligated onto the 5'(TaqI) end of the fragment:

50 5' - CATG GGA AAG GAA TTT ACC TTA GAC TTC T - 3'
 3' - CCT TTC CTT AAA TGG AAT CTG AAG AGC - 5'
 peptide: fmet-Gly-Lys-Glu-Phe-Thr-Leu-Asp-Phe-Ser
 1/2 1/2
 NcoI TaqI

55 This oligonucleotide sequence provides an fmet-Gly coding sequence followed by a sequence coding for the first eight amino acids of the mature SLT A subunit, to replace the section of the natural gene (coding for the toxin signal peptide and same eight amino acids of the mature SLT A subunit) which was cleaved off during TaqI digestion of the gene. Also provided by the oligonucleotide linker is a 1/2 NcoI site at the 5' end of the construct, to permit expression from the *trc* promoter of the hybrid plasmid.

The following oligonucleotide sequence, which regenerates the coding region (cleaved off by XmnI diges-

tion) for the carboxyl end of the SLT A subunit up to the initial Cys codon, and introduces an Apal restriction site, is ligated to the 3' (XmnI) end of the sltA gene fragment :

5' - ATT TCT TTT GGA AGC ATT AAT GCA ATT CTG-
 3' - TAA AGA AAA CCT TCG TAA TTA CGT TAA GAC-
 peptide: Ile-Ser-Phe-Gly-Ser-Ile-Asn-Ala-Ile-Leu-
 1/2
XmnI

(cont.) -GGA AGC GTG GCA TTA ATA CTG AAT GGG CC -3'
 -CCT TCG CAC CGT AAT TAT GAC TTA C -5'
 -Gly-Ser-Val-Ala-Leu-Ile-Leu-Asn-Gly-Pro
 1/2 Apal

The NcoI-Apal sltA gene sequence can be ligated into a NcoI + Apal-digested plasmid pPA123 (Fig. 7) to yield a SLTA-diphtheria toxin B'-IL2 ("SLTA/DTB'/IL2 hybrid") gene that can be expressed in E.coli from the trc promoter on the plasmid (see Fig. 9).

An alternative cloning strategy for constructing a plasmid encoding a Shiga-like toxin A-diphtheria toxin B'-IL2 hybrid is illustrated in Fig. 10.

Purified SLTA/DTB'/IL2 hybrid protein would be useful as a treatment for conditions involving overproduction of cells bearing IL2 receptors, such as certain T-cell lymphomas and organ transplant rejection crises. As is the case for diphtheria toxin-IL2, the IL2 portion of the hybrid causes the hybrid to attach specifically to IL2-receptor-bearing cells, so that the enzymatic portion of the hybrid can be inserted into the targeted cell; the enzymatic portions of both types of hybrid toxins then act on the protein synthesis machinery in the cell to shut down protein synthesis, thus killing the cell. The difference between these two types of hybrid toxins is the nature of their enzymatic activities: the enzymatic portion of diphtheria toxin-IL2 hybrid catalyzes the ADP-ribosylation by nicotinamide adenine dinucleotide of Elongation Factor 2, thereby inactivating this factor which is necessary for protein synthesis, while the enzymatic portion of SLTA/DTB'/IL2 hybrid is a ribonuclease capable of cleaving ribosomal RNA at a critical site, thereby inactivating the ribosome. SLTA/DTB'/IL2 hybrid would therefore be useful as a treatment for the same indications as diphtheria toxin-IL2 hybrid, and could be substituted if, for example, the proliferating T-cells develop a resistance to the latter hybrid toxin.

Example 4. Construction of ricin A-diphtheria toxin B'-IL2 gene, and use of the resultant hybrid protein

A genomic clone bank of castor bean (Ricinus communis) DNA is prepared as described in Halling et al., Nucl. Acids Res. 13:8019-8033, 1985, and a ~780bp BanI fragment of the ricin gene, corresponding to most of the ricin A domain (the enzymatic domain) and a portion of the ricin A-to-B linker peptide, is isolated therefrom (see Fig. 11). The following synthetic oligonucleotide is ligated onto both ends of the fragment, phosphorylating only the bottom strand of DNA shown:

5' - C ATG GCT ATA TTC CCC AAA CAA TAC CCA ATT-
 3' - CGA TAT AAG GGG TTT GTT ATG GGT TAA-
 Peptide: fmet-Ala-Ile-Phe-Pro-Lys-Gln-Tyr-Pro-Ile-
 1/2
NcoI

(cont.) -ATA AAC TTT ACC ACA GCG G - 3'
 -TAT TTG AAA TGG TGT CGC CCA CG - 5'
 -Ile-Asn-Phe-Thr-Thr-Ala-Gly-Ala
 1/2
BanI

The resulting ligated fragment (illustrated in Fig. 11) is partially digested with FspI, and the ~780bp band corresponding to a BanI-FspI ricin A gene fragment with a NcoI-BanI linker at the 5' end is isolated (see Fig. 11). The NcoI-BanI linker supplies the mature ricin A N-terminal amino acid codons which were cleaved from the

fragment during BanI digestion, as well as the codons for fmet-Ala to replace the natural ricin A signal peptide.

The following oligonucleotide is ligated onto the 3' (FspI) blunt end of the fragment, phosphorylating only the top strand shown :

```

5' - GCA CCT CCA CCA TCG TCA CAG TTT GGG CC - 3'
3' - CGT GGA GGT GGT AGC AGT GTC AAA C - 5'
Peptide: Ala-Pro-Pro-Pro-Ser-Ser-Gln-Phe-Gly-Pro
1/2                                     1/2
FspI                                     ApaI

```

This linker supplies the ricin A coding sequence cleaved from the 3' end of the ricin A fragment during the FspI digest, plus a 1/2 Apal site for fusion to plasmid pPA123.

The completed construct is then cloned into NcoI/Apal-digested pPA123 to yield a ricin A-diphtheria toxin B'-IL2 gene that can be expressed in E.coli from the lac promoter on the plasmid (see Fig. 12).

Purified ricin A-diphtheria toxin B'-IL2 hybrid, like the SLTA/DTB'/IL2 hybrid of Example 3, inactivates ribosomes in cells bearing IL2 receptors, resulting in cessation of protein synthesis and death of the targeted cells. The ricin A hybrid would thus have the same applications as SLTA/DTB'/IL2 hybrid, as discussed in Example 3.

Example 5. Construction of phenylalanine hydroxylase- diphtheria toxin B gene, and use of the resultant hybrid protein.

A human liver cDNA library is screened for phenylalanine hydroxylase ("PH") cDNA as described by Kwok et al., Biochem. 24 :556-561, 1985. The approximately 1160-bp EcoRII-AflII fragment that encodes most of the PH protein is isolated (see Figs. 13 and 14). The following linkers are ligated onto the 5' EcoRII end in order to recreate the 5' coding sequences and incorporate an NcoI site :

```

5' - C ATG TCC ACT GCG GTC CTG GAA AAC - 3'
3' - AGG TGA CGC CAG GAC CTT TTG GGT CC - 5'
fmet-Ser-Thr-Ala-Val-Leu-Gln-Asn-Pro-Gly
NcoI                                     1/2
sticky end                             EcoRII

```

The following linkers are ligated onto the 3' AflII end to complete the PH coding sequence and to include an Apal restriction site in the correct translational reading frame for fusion to diphtheria toxin fragment B sequences (Fig. 14):

```

5' - TT AAG ATT TTG GCT GAT TCC ATT AAC AGT GAA ATT GGA-
3' - C TAA AAC CGA CTA AGG TAA TTG TCA CTT TAA CCT-
Lys-Ile-Leu-Ala-Asp-Ser-Ile-Asn-Ser-Glu-Ile-Gly-
1/2
AflII

```

```

(cont.) -ATC CTT TGC AGT GCC CTC CAG AAA ATA AAG GGG CC - 3'
-TAG GAA ACG TCA CGG GAG GTC TTT TAT TTC C - 5'
-Ile-Leu-Cys-Ser-Ala-Leu-Gln-Lys-Ile-Lys-Gly-Pro
1/2
ApaI

```

This fragment is then ligated onto the NcoI-Apal digested pPA123 vector (Fig. 14) resulting in a plasmid that encodes phenylalanine hydroxylase fused to diphtheria toxin B'-IL-2. Finally, this plasmid is digested with EcoRI and SphI to remove IL-2 encoding sequences, which are replaced by the approximately 230 bp SphI-EcoRI fragment of corynebacteriophage β that encodes the 3' end of diphtheria toxin fragment B (Fig. 14). This completed construct codes for a PH-diphtheria toxin B hybrid protein that can be expressed in E.coli from the lac promoter on the plasmid (see Fig. 14).

The inherited disorder phenylketonuria, in which the inability to metabolize phenylalanine leads to an

accumulation of excess phenylalanine and possible brain damage in affected individuals, has been attributed to a genetic deficiency of the enzyme PH. By constructing a molecule in which active PH enzyme is linked to the cell-binding and translocation domains of diphtheria toxin Fragment B, the enzyme can be targeted to and incorporated into the broad range of cells which native diphtheria toxin normally attacks, achieving the widespread therapy that is called for by a defect such as phenylketonuria. This cloning strategy would be applicable to the construction of other hybrids useful in the treatment of other genetic defects.

Example 6. Construction of an HIV protease-binding protein-diphtheria toxin B'-IL2 gene, and use of the resultant hybrid protein.

A recombinant gene expressing a novel protein, an antigen-binding, single-polypeptide-chain analog of a monoclonal antibody composed of an antibody variable light-chain amino acid sequence (V_L) linked to a variable heavy-chain sequence (V_H) by a linker peptide, is constructed by the method of Bird et al., Science 242:423-426, 1988, based upon the V_L and V_H sequences of a monoclonal antibody specific for and able to inactivate HIV protease (Hansen et al., Embo J. 7:1785-1791, 1988) and a linker peptide designed by the method of Bird et al. The ends of the V_L -linker- V_H gene are modified with appropriate restriction enzymes and synthetic DNA linkers in order to produce an intact V_L -linker- V_H gene having 1/2 of a *NcoI* site at the 5' end and 1/2 of an *Apal* site at the 3' end. The gene is then cloned into *NcoI* + *Apal*-digested pPA123 to produce a plasmid expressing, from the *trc* promoter, an HIV protease-binding protein-diphtheria toxin B'-IL2 hybrid protein ("HIVP-BP/DTB'/IL2 hybrid").

Following expression of the recombinant gene in *E. coli*, the HIVP-BP/DTB'/IL2 hybrid protein can be isolated and used to treat an HIV infection in a human patient. The HIV virus infects and proliferates within T-cells, commandeering the cellular protein synthesis machinery to produce multiple copies of its own proteins. One viral protein in particular, the HIV protease, plays a critical role in the processing of other viral proteins; identifying a way to inactivate this protease within the infected cell has been the focus of much recent effort toward developing an effective AIDS therapy (see, e.g., Hansen et al.). The HIVP-BP/DTB'/IL2 hybrid delivers a viral protease-specific inhibitor specifically to activated T-cells bearing the IL2 receptor, and thus can be effective at low dosages, with little or no toxicity to other types of cells. This technology could be applied as well to other viral infections or genetic disorders.

Other Embodiments

Other embodiments are within the following claims. For example, any cell-specific polypeptide ligand can be used which has a binding domain specific for the particular class of cells which are to be labeled. Polypeptide hormones are useful such ligands. Hybrid protein made using the binding domain of α or β MSH, for example, can selectively bind to melanocytes, rendering hybrids, once labelled with a detectable label, useful in the diagnosis of melanoma and the *in vivo* and *in vitro* detection of metastatic melanoma foci. Such a hybrid, when attached to an enzymatically-active portion of a toxin molecule instead of to a detectable label, could be utilized to deliver that toxic activity specifically to the target melanoma cells. Other ligands provide different specificities: e.g., the binding domain of substance P recognizes receptors on the surfaces of neurons involved in the transmission of pain, so that labeled hybrids made using substance P can be used to map areas of the nervous system containing substance P receptors. Other specific-binding ligands which can be used include insulin, somatostatin, EGF, and Interleukins I, II, III, IV and VI. Interleukin II is of particular importance because of its role in allergic reactions and autoimmune diseases such as Systemic Lupus Erythematosus (SLE), involving activated T cells. Other useful polypeptide ligands having cell-specific binding domains are follicle stimulating hormone (specific for ovarian cells), luteinizing hormone (specific for ovarian cells), thyroid stimulating hormone (specific for thyroid cells), vasopressin (specific for uterine cells, as well as bladder and intestinal cells), prolactin (specific for breast cells), and growth hormone (specific for certain bone cells). Alternatively, a relatively indiscriminate cell-binding ligand (such as that of diphtheria toxin or ricin toxin) capable of binding to a wide variety of cell types in an organism can be used to effect widespread introduction of a specific chemical entity into cells of that organism, where more specific targeting is not the goal.

For a number of cell-specific ligands, the region within each such ligand in which the binding domain is located is now known. Furthermore, recent advances in solid phase polypeptide synthesis enable those skilled in this technology to determine the binding domain of practically any such ligand, by synthesizing various fragments of the ligand and testing them for the ability to bind to the class of cells to be labeled. Thus, the hybrid molecules of the invention need not include an entire ligand, but rather may include only a fragment of a ligand which exhibits the desired cell-binding capacity. Likewise, analogs of the ligand or its cell-binding region having minor sequence variations may be synthesized, tested for their ability to bind to cells, and incorporated into

the hybrid molecules of the invention. Other potential ligands include monoclonal antibodies or antigen-binding, single-chain analogs of monoclonal antibodies, where the antigen is a receptor or other moiety expressed on the surface of the target cell membrane.

The translocation function of the hybrid molecule may be supplied by an appropriate piece of a polypeptide other than diphtheria toxin, but which is capable of translocating in a manner analogous to that of diphtheria toxin (e.g., *Pseudomonas* exotoxin A, botulinum, neurotoxin, or ricin), or in any other manner which accomplishes the objective of translocating the functional "third part" of the hybrid molecule into the cell's cytoplasm.

The chemical entity to be inserted into the cell can vary widely and still be within the invention. For example, the enzyme which is genetically deficient in Tay-Sachs disease, hexosaminidase A, could be attached to a hybrid having a cell-binding domain specific for the cells most affected by the disease, nerve cells. Patients suffering from type 2 glycogenosis might be treated with a hybrid comprising α -1,4-glucosidase linked to the translocation segment of diphtheria toxin linked to insulin, which would largely target muscle cells, hepatocytes, and lymphocytes. (See Poznansky et al., Science 223:1304-1306, 1984.) These are simply examples: any other enzyme deficiency disease for which the natural enzyme or its gene has been sequenced (or is amenable to sequencing by one skilled in the art, without undue experimentation) could be treated with a hybrid comprising the active enzyme linked to a translocation domain linked to an appropriate cell-binding ligand.

Intracellular viral and bacterial infections could be treated by an appropriate hybrid: for example, a hybrid which delivers into the cell a potent antibiotic, or a recombinant V_L -linker- V_H antigen-binding polypeptide which specifically binds viral particles or proteins.

Likewise, the hybrid of the invention will be useful for specifically destroying certain cells. Besides the cholera toxin A_1 -hybrid, ricin A-hybrid and Shiga-like toxin A-hybrid exemplified above, a cell-killing function may be provided by the enzymatically-active portion of any polypeptide toxin, including but not limited to LT toxin, C3 toxin, Shiga toxin, pertussis toxin, tetanus toxin and *Pseudomonas* exotoxin A. Cells to be targeted might include cancer cells, virus-infected cells, or adipocytes.

The invention includes biologically active mutational analogs of hybrid polypeptides described above. By manipulating the recombinant DNA sequence encoding the subject hybrid polypeptide using methods well known to those of ordinary skill in the art of genetic engineering, a series of mutations involving deletions and/or substitutions of individual or multiple base pairs in such recombinant DNA sequence is first created. Each such mutated sequence is then inserted into an expression vector and expressed in an appropriate expression system. The biological activity of the mutational analog so produced can then be compared to that exhibited by the hybrid molecule of which it is an analog (the "parent polypeptide"). The particular assay used will depend upon the particular enzymatic activity and cell-binding specificity of the parent polypeptide. For example, mutational analogs of the Shiga-like toxin A/diphtheria toxin B'/IL2 (SLT/DTB'/IL2) hybrid, the cholera toxin A_1 /diphtheria toxin B'/IL2 (CTA/DTB'/IL2) hybrid, and the ricin A/diphtheria toxin B'/IL2 hybrid may be tested and compared to their respective parent polypeptides in the following cell cytotoxicity assay, which is specific for toxins capable of binding to IL2 receptor-bearing cells.

40. Assay

Cultured HUT 102/6TG (Tsuda et al., Proc. Natl. Acad. Sci. USA 83:9694, 1986) or YT2C2 (Teshigawari et al., J. Exp. Med. 165:223, 1987) cells are maintained in RPMI 1640 medium (Gibco, Grand Island, N.Y.) supplemented with 10% fetal bovine serum (Collect, GIBCO), 2mM glutamine, and penicillin and streptomycin to 50 IU and 50 μ g/ml, respectively. Cells are seeded in 96-well V-bottomed plates (Linbro-Flow Laboratories, McLean, VA) at a concentration of 5×10^4 per well in complete medium. Putative toxins are added to varying concentrations (10^{-12} M to 10^{-6} M) and the cultures are incubated for 18 hrs. at 37°C in a 5% CO₂ atmosphere. Following incubation, the plates are centrifuged for 5 min. at 170 x g, and the medium removed and replaced with 200 μ l leucine-free medium (MEM, Gibco) containing 1.0 μ Ci/ml [¹⁴C]-leucine (New England Nuclear, Boston, MA). After an additional 90 min. at 37°C, the plates are centrifuged for 5 min. at 170 x g, the medium is removed and the cells are lysed by the addition of 4 M KOH. Protein is precipitated by the addition of 10% trichloroacetic acid and the insoluble material is then collected on glass fiber filters using a cell harvester (Skatron, Sterling, VA). Filters are washed, dried, and counted according to standard methods. Cells cultured with medium alone serve as the control.

Where IL4 replaces IL2 as the cell-binding portion of the resulting hybrid, the hybrid and its mutational analogs may be tested by a similar assay utilizing CT4R cells (William E. Paul, NIH), P815 cells (ATCC), or CTLL2 (ATCC), seeded at 1×10^4 cells per well and incubated for 40 hours.

Claims

- 5 1. A hybrid molecule comprising a first part, a second part, and a third part connected by covalent bonds,
 (a) said first part comprising a portion of the binding domain of a cell-binding ligand, said portion being
 effective to cause said hybrid molecule to bind to a cell of an animal ;
 (b) said second part comprising a portion of a translocation domain of a protein capable of translocating
 said third part across the cytoplasmic membrane of said cell ; and
 10 (c) said third part comprising a chemical entity to be introduced into said cell, provided that (i) said hybrid
 molecule is produced by expression of a recombinant DNA molecule encoding said hybrid molecule,
 and (ii) said second part and said third part are not segments of the same naturally-occurring polypep-
 tide toxin.
- 15 2. A hybrid molecule comprising a first part, a second part, and a third part connected by covalent bonds,
 (a) said first part comprising a portion of the binding domain of a cell-binding ligand, said portion being
 effective to cause said hybrid molecule to bind to a cell of an animal ;
 (b) said second part comprising a portion of a translocation domain of a protein capable of translocating
 said third part across the cytoplasmic membrane of said cell ; and
 20 (c) said third part comprising a chemical entity to be introduced into said cell, provided that (i) said first
 part and said second part are not segments of the same naturally-occurring polypeptide toxin, and (ii)
 said second part and said third part are not segments of the same naturally-occurring polypeptide toxin.
- 25 3. The hybrid molecule of claim 1 or claim 2, wherein said protein is a naturally-occurring toxin.
4. The hybrid molecule of claim 2, wherein said protein is selected from the group consisting of diphtheria
 toxin and Pseudomonas exotoxin A.
5. The hybrid molecule of claim 1 or claim 2, wherein said ligand is a polypeptide hormone.
- 30 6. The hybrid molecule of claim 5, wherein said hormone is selected from the group consisting of insulin, Inter-
 leukin II, Interleukin IV, Interleukin VI, and EGF.
7. The hybrid molecule of claim 2, wherein said ligand is a steroid hormone.
- 35 8. The hybrid molecule of claim 1 or claim 2, wherein said ligand is an antigen-binding, single-chain analog
 of a monoclonal antibody, and said antigen is expressed on the surface of said cell.
9. The hybrid molecule of claim 1 or claim 2, wherein said ligand is a polypeptide toxin capable of binding to
 40 said cell.
10. The hybrid molecule of claim 2, wherein any adjacent two of said parts are both polypeptides, and said
 covalent bond between said two parts is a peptide bond.
- 45 11. The hybrid molecule of claim 10, wherein said first part and said third part each comprises a polypeptide
 and said hybrid molecule comprises a recombinant protein.
12. The hybrid molecule of claim 1 or claim 2, wherein said chemical entity comprises an enzymatically-active
 portion of an enzyme.
- 50 13. The hybrid molecule of claim 12, wherein said enzyme is a toxin.
14. The hybrid molecule of claim 13, wherein said enzyme is selected from the group consisting of cholera
 toxin, LT toxin, C3 toxin, Shiga toxin, E.coli Shiga-like toxin, ricin toxin, pertussis toxin, tetanus toxin,
 55 diphtheria toxin and Pseudomonas exotoxin A.
15. The hybrid molecule of claim 14, wherein said enzyme is cholera toxin.
16. The hybrid molecule of claim 12, wherein said enzyme is selected from the group consisting of hexosami-
 nidase A, α -1,4-glucosidase, phenylalanine hydroxylase, a protease and a nuclease.

17. The hybrid molecule of claim 12, wherein said enzymatically-active portion supplies an enzymatic activity in which said cell is deficient.
18. The hybrid molecule of claim 17, wherein said deficiency is genetic.
19. The hybrid molecule of claim 1 or claim 2, wherein said chemical entity comprises an antigen-binding, single-chain analog of a monoclonal antibody.
20. The hybrid molecule of claim 19, wherein said antigen is a viral protein.
21. The hybrid molecule of claim 20, wherein said viral protein is HIV protease.
22. A hybrid polypeptide molecule comprising CTA/DTB/IL2 hybrid.
23. A hybrid polypeptide molecule comprising SLTA/DTB/IL2 hybrid.
24. A hybrid polypeptide molecule comprising ricin A-diphtheria toxin B'-IL2 hybrid.
25. A hybrid polypeptide molecule encoded by the phenylalanine hydroxylase-diphtheria toxin fragment B gene of Fig. 14.
26. A hybrid polypeptide molecule comprising HIVP-BP/DTB/IL2 hybrid.
27. A hybrid polypeptide molecule comprising a biologically active mutational analog of the hybrid molecule of any of claims 22-26.
28. A hybrid polypeptide molecule comprising an enzymatically-active portion of Shiga-like toxin A and a portion of a binding domain of a cell-binding polypeptide ligand, said portion of said binding domain being effective to cause said hybrid molecule to bind to a cell of an animal.
29. The hybrid molecule of claim 28, wherein said polypeptide ligand is IL2.
30. A method of treating an animal having a disease characterized by the enzyme deficiency of claim 17, said method comprising administering to said animal an effective amount of the hybrid molecule of claim 17.
31. A method of raising the cyclic AMP level within a target cell, said method comprising contacting said target cell with the hybrid molecule of claim 15.
32. The method of claim 31, wherein said target cell is a T cell and said hybrid molecule comprises at least a portion of the binding domain of Interleukin II.
33. A method of treating a human patient infected with HIV, said method comprising administering to said patient an effective amount of the hybrid molecule of claim 21.
34. A recombinant DNA molecule encoding the hybrid protein of claim 1 or claim 2.
35. A vector comprising the recombinant DNA molecule of claim 34.
36. A cell containing the recombinant DNA molecule of claim 34.
37. The cell of claim 36, wherein said cell is capable of expressing said recombinant DNA molecule.
38. A method of preparing the hybrid molecule of claim 1 or claim 2, said method comprising providing a cell containing a recombinant DNA molecule encoding said hybrid molecule (the "transformed cell"), and permitting said transformed cell to express said recombinant DNA molecule.




FIG. 1




FIG. 2




FIG. 3




FIG. 4

FIG. 5-1

10 20 30 40 50 60
 ATGGTAAAGATAATATTTGTGTTTTTATTTTCTTATCATCATTTTCATATGCAAATGAT
 METValLysIleIlePheValPhePheIlePheLeuSerSerPheSerTyrAlaAsnAsp

70 80 90 100 110 120
 GATAAGTTATATCGGGCAGATTCTAGACCTCCTGATGAAATAAAGCAGTCAGGTGGTCTT
 AspLysLeuTyrArgAlaAspSerArgProProAspGluIleLysGlnSerGlyGlyLeu

130 140 150 160 170 180
 ATGCCAAGAGGACAGAGTCAGTACTTTGACCGAGGTACTCAAATGAATATCAACCTTTAT
 METProArgGlyGlnSerGlnTyrPheAspArgGlyThrGlnMETAsnIleAsnLeuTyr

190 200 210 220 230 240
 GATCATGCAAGAGGAACTCAGACGGGATTTGTTAGGCACGATGATGGATATGTTTCCACC
 AspHisAlaArgGlyThrGlnThrGlyPheValArgHisAspAspGlyTyrValSerThr

250 260 270 280 290 300
 TCAATTAGTTTGAGAAGTGCCCACTTAGTGGGTCAAACCTATATTGTCTGGTCATTCTACT
 SerIleSerLeuArgSerAlaHisLeuValGlyGlnThrIleLeuSerGlyHisSerThr

310 320 330 340 350 360
 TATTATATATATGTTATAGCCACTGCACCCAACATGTTTAACGTTAATGATGTATTAGGG
 TyrTyrIleTyrValIleAlaThrAlaProAsnMETPheAsnValAsnAspValLeuAla

370 380 390 400 410 420
 GCATACAGTCCTCATCCAGATGAACAAGAAGTTTCTGCTTTAGGTGGGATTCCATACTCC
 AlaTyrSerProHisProAspGluGlnGluValSerAlaLeuGlyGlyIleProTyrSer

FIG. 5-2

430 440 450 460 470 480
 CAAATATATGGATGGTATCGAGTTCATTTGGGGTGCTTGATGAACAATTACATCGTAAT
 Gln Ile Tyr Gly Trp Tyr Arg Val His Phe Gly Val Leu Asp Glu Gln Leu His Arg Asn
 490 500 510 520 530 540
 AGGGGCTACAGAGATAGATATTACAGTAACTTAGATATTGCTCCAGCAGCAGATGGTTAT
 Arg Gly Tyr Arg Asp Arg Tyr Tyr Ser Asn Leu Asp Ile Ala Pro Ala Ala Asp Gly Tyr
 550 560 570 580 590 600
 GGATTGGCAGGTTTCCCTCCGGAGCATAGAGCTTGGAGGGAAGAGCCGTGGATTCATCAT
 Gly Leu Ala Gly Phe Pro Pro Glu His Arg Ala Trp Arg Glu Glu Pro Trp Ile His His
 610 620 630 640 650 660
 GCACCGCCGGGTTGTGGGAATGCTCCAAGATCATCGATGAGTAATACTTGCGATGAAAAA
 Ala Pro Pro Gly Cys Ala Asn Ala Pro Arg Ser Ser MET Ser Asn Thr Cys Asp Glu Lys
 670 680 690 700 710 720
 ACCCAAAGTCTAGGTGTAAAATTCCTTGACGAATACCAATCTAAAGTTAAAAGACAAATA
 Thr Gln Ser Leu Gly Val Lys Phe Leu Asp Glu Tyr Gln Ser Lys Val Lys Arg Gln Ile
 730 740 750 760 770 STOP 780
 TTTTCAGGCTATCAATCTGATATTGATACACATAATAGAATTAAGGATGAATTATGATTA
 Phe Ser Gly Tyr Gln Ser Asp Ile Asp Thr His Asn Arg Ile Lys Asp Glu Leu — Leu




FIG. 7




FIG. 8-I

10 20 30 40 50 60
 | | | | |
 ATGAAAATAATTATTTTATAGAGTGCTAACTTTTTCTTTGTTATCTTTTCAGTTAATGTG
 METLysIleIleIlePheArgValLeuThrPhePhePheValIlePheSerValAsnVal
 70 80 90 100 110 120
 | | | | |
 GTGGCGAAGGAATTTACCTTAGACTTCTCGACTGCAAAGACGTATGTAGATTCGCTGAAT
 ValAlaLysGluPheThrLeuAspPheSerThrAlaLysThrTyrValAspSerLeuAsn
 130 140 150 160 170 180
 | | | | |
 GTCATTCGCTCTGCAATAGGTACTCCATTACAGACTATTTTCATCAGGAGGTACGCTCTTA
 ValIleArgSerAlaIleGlyThrProLeuGlnThrIleSerSerGlyGlyThrSerLeu
 190 200 210 220 230 240
 | | | | |
 CTGATGATTGATAGTGGCTCAGGGGATAATTTGTTTGCAGTTGATGTCAGAGGGATAGAT
 LeuMETIleAspSerGlySerGlyAspAsnLeuPheAlaValAspValArgGlyIleAsp
 250 260 270 280 290 300
 | | | | |
 CCAGAGGAAGGGCGGTTTAATAATCTACGGCTTATTGTTGAACGAAATAATTTATATGTG
 ProGluGluGlyArgPheAsnAsnLeuArgLeuIleValGluArgAsnAsnLeuTyrVal
 310 320 330 340 350 360
 | | | | |
 ACAGGATTTGTTAACAGGACAAATAATGTTTTTATCGCTTTGCTGATTTTTCACATGTT
 ThrGlyPheValAsnArgThrAsnAsnValPheTyrArgPheAlaAspPheSerHisVal
 370 380 390 400 410 420
 | | | | |
 ACCTTTCCAGGTACAACAGCGGTTACATTGTCTGGTGACAGTAGCTATACCAGTTACAG
 ThrPheProGlyThrThrAlaValThrLeuSerGlyAspSerSerTyrThrThrLeuGln

FIG. 8-2




FIG. 8-3

850 860 870 880 890 900
 TCTATGTGTCCGGCAGATGGAAGAGTCCGTGGGATTACGCACAATAAAATATTGTTGTGG
 SerMETCysProAlaAspGlyArgValArgGlyIleThrHisAsnLysIleLeuLeuTrp

910 920 930 940 950 960
 GATTGATCCACTCTGGGGCAATTCTGATGCGCAGAACTATTAGCAGTTGAGGGGGTAAA
 AspSerSerThrLeuGlyAlaIleLeuMETArgArgThrIleSerSer---GlyGlyLys

970 980 990 1000 1010 1020
 ATGAAAAAACATTATTAATAGCTGCATCGCTTTCATTTTTTCAGCAAGTGCCTGGCG
METLysLysThrLeuLeuIleAlaAlaSerLeuSerPhePheSerAlaSerAlaLeuAla

1030 1040 1050 1060 1070 1080
 ACGCCTGATTGTGTAAGTGGAAAGGTGGAGTATACAAATATAATGATGACGATACCTTT
 ThrProAspCysValThrGlyLysValGluTyrThrLysTyrAsnAspAspAspThrPhe

1090 1100 1110 1120 1130 1140
 ACAGTTAAAGTGGGTGATAAAGAATTATTACCAACAGATGGAATCTTCAGTCTCTTCTT
 ThrValLysValGlyAspLysGluLeuPheThrAsnArgTrpAsnLeuGlnSerLeuLeu

1150 1160 1170 1180 1190 1200
 CTCAGTGCGCAAATTACGGGGATGACTGTAACCATTAATACTAATGCCTGTCATAATGGA
 LeuSerAlaGlnIleThrGlyMETThrValThrIleLysThrAsnAlaCysHisAsnGly

1210 1220 1230
 GGGGGATTGAGCGAAGTTATTTTTCGTTGA
 GlyGlyPheSerGluValIlePheArg---






FIG. 9





1 TCGACATTATATGATTTTAAATCAATTCCGTTTCTAATTTATAATTATTTTCGTTAAACCAATCAA
 66 TTCCCTTTAAACACTGCTTATGCATATTCTGTCTCAATTTATATATGGCATTGCATTCTTCCGTAT
 132 TAATTTATAAGTTCACTTTTTATTGATCAAGTATTTGTGGTTTTCTTTATATAAAAAAATGTATTA
 198 GTGTTTTTCTGTATTAATTTTATAAGTTCATCTTTATGAGAATGCTAATGTATTTGGACAGCCAAT
 264
 M K P G G N T I V I W M Y
 AAAATTCCAGAATTGCTGCAATCAAGGATGAAACCGGGAGGAAATACTATTGTAATATGGATGTAT
 330 L Signal Peptide
 A V A T W L C F G S I S G W S F T L E D N N
 GCAGTGGCAACATGGCTTTGTTTGGATCCACCTCAGGGTGGTCTTTCACATTAGAGGATAACAAC
 396 Signal Peptide
 I F P K Q Y P I I N F I T A G A T V Q S Y I
 ATATTCCTCCAAACAATACCCAATTATAAACTTTACCACAGCGGGTGCCACTGTGCAAAGCTACACA
 LA-chain Ban I
 N F I R A V R G R L T T G A D V R H E I P V
 AACTTTATCAGAGCTGTTGCGGGTCGTTTAACTGAGCTGATGTGAGACATGAAATACCAAGT
 519
 L P N R V G L P I N Q R F I L V E L S N H A
 TTGCCAAACAGAGTTGGTTTGCCTATAAACCAACGGTTTATTTTAGTTGAACCTCTCAAATCATGCA
 594
 E L S V T L A L D V T N A Y V V G Y R A G N
 GAGCTTTCTGTTACATTAGCGCTGGATGTCACCAATGCATATGTGGTCGGCTACCGTGCTGGAAT
 660
 S A Y F F H P D N Q E D A E A I T H L F T D
 AGCGCATATTTCTTTCATCCTGACAATCAGGAAGATGCAGAAGCAATCACTCATCTTTTCACTGAT
 726
 V Q N R Y T F A F G G N Y D R L E Q L A G N
 GTTCAAAATCGATATACATTGCGCTTTGGTGGTAATTATGATAGACTTGAACAACTTGCTGGTAAT
 792
 L R E N I E L G N G P L E E A I S A L Y Y Y
 CTGAGAGAAAATATCGAGTTGGGAAATGGTCCACTAGAGGAGGCTATCTCAGCGCTTTATTATTAC
 858
 S T G G T Q L P T L A R S F I I C I Q M I S
 AGTACTGGTGGCACTCAGCTTCCAACCTCTGGCTCGTTTCTTTATAATTTGCATCCAAATGATTICA
 924 Fsp I
 E A A R F Q Y I E G E M R T R I R Y N R R S
 GAAGCAGCAAGATTCCAATATATTGAGGGAGAAATGCGCAGGAGAATTAGGTACAACCGGAGATCT
 990
 A P D P S V I T L E N S W G R L S T A I Q E
 GCACCAGATCCTAGCGTAATTACACTTGAGAATAGTTGGGGGAGACTTCAACTGCAATTCAAGAG
 1056
 S N Q G A F A S P I Q L Q R R N G S K F S V
 TCTAACCAAGGAGCCTTTGCTAGTCCAATTCAACTGCAAGACGTAATGGTTCCAAATTCAGTGTG
 1122 Fsp I
 Y D V S I L I P I I A L M V Y R C A P P P S
 TACGATGTGAGTATATTAATCCCTATCATAGCTCTCATGGTGTATAGATGCGCACCTCCACCATCG

FIG. 11-I

1188 Ban I
 S Q F S L L I R P V V P N F N A D V C M D P
 TCACAGTTTTCTTTGCTTATAAGGCCAGTGGTACCAAATTTTAATGCTGATGTTTGTATGGATCCT
 A-chain Linker Peptide B-chain
 1254
 E P I V R I V G R N G L C V D V R D G R F H
 GAGCCCATAGTGCATATCGTAGGTCGAAATGGTCTATGTGTGATGTTAGGGATGGAAGATTCCAC
 1320
 N G N A I Q L W P C K S N T D A N Q L W T L
 AACGGAAACGCAATACAGTTGTGGCCATGCAAGTCTAATACAGATGCAAATCAGCTCTGGACTTTG
 1386
 K R D N T I R S N G K C L T T Y G Y S P G V
 AAAAGAGACAATACTATTCGATCTAATGGAAAGTGTTTAACTACTTACGGGTACAGTCCGGGAGTC
 1452
 Y V M I Y D C N T A A T D A T R W Q I W D N
 TATGTGATGATCTATGATTGCAATACTGCTGCAACTGATGCCACCCGCTGGCAAATATGGGATAAT
 1518
 G T I I N P R S S L V L A A T S G N S G T T
 GGAACCATCATAAATCCCAGATCTAGTCTAGTTTTAGCAGCGACATCAGGGAACAGTGGTACCACA
 1584
 L T V Q T N I Y A V S Q G W L P T N N T Q P
 CTTACAGTGCAAACCAACATTTATGCCGTTAGTCAAGGTTGGCTTCTACTAATAATACACAACCT
 1650
 F V T T I V G L Y G L C L Q A N S G Q V W I
 TTTGTGACAACCATTTGTTGGGCTATATGGTCTGTGCTTGCAAGCAAATAGTGGACAAGTATGGATA
 1716
 E D C S S E K A E Q Q W A L Y A D G S I R P
 GAGGACTGTAGCAGTGAAAAGGCTGAACAACAGTGGGCTCTTTATGCAGATGGTTCAATACGTCCT
 1782
 Q Q N R D N C L T S D S N I R E T V V K I L
 CAGCAAAACCGAGATAATTGCCTTACAAGTGATTCTAATATACGGGAAACAGTTGTCAAGATCCTC
 1848
 S C G P A S S G Q R W M F K N D G T I L N L
 TCTTGTGGCCCTGCATCCTCTGGCCAACGATGGATGTTCAAGAATGATGGAACCATTTTAAATTG
 1914
 Y S G L V L D V R A S D P S L K Q I I L Y P
 TATAGTGGGTTGGTGTAGATGTGAGGGCATCGGATCCGAGCCTTAAACAAATCATTCTTTACCCT
 1980
 L H G D P N Q I W L P L F * *
 CTCCATGGTGACCCAAACCAATATGGTTACCATTATTTTGA TAGACAGATTACTCTCTTGCAGTG
 2046 B-chain
 TGTATGTCCTGCCATGAAAATAGATGGCTTAAATAAAAAGGACATTGTAAATTTTGAAGTAAAG
 2112
 GACAGCAAGTTATTGCAGTCCAGTATCTAATAAGAGCACAACCTATTGTCTTGTGCATTCTAAATTT
 2178
 ATGGATGAATGTATGAATAAAGCTAATTATTTTGGTCATCAGACTTGATATCTTTTGAATAAAAT
 2244
 AAATAATAATGTTTTTTCAAACCTATAAACTAATGAATGATATGAATATAAATGCGGAGACTAGT
 2310
 CAATCTTTTATGTAATTCTATGATGATAAAAGCTT

FIG. II-2




FIG. 12

CTT CAT CGT CGT	15	CCA ACT GAC CTT GAG	30	TGT TAG TTT CGC GGT AAG	45	TTT GGG TAT AAG	60	TGC CAC CAC CAG TGC	75	CGG
CAG TGT AGT CAG	90	TAG TTT GTT GCT GGA	105	CGT TAC CGC CAA	120	ACT GCG TGT TAC CGC	135	GAT TAG ACT GTG	150	GCT
GCT GGC GTT GAG	165	GGA AAC CTG CCT GTA	180	CGT GAG GCC CTA AAA	195	AGC CAG AGA CCT CAC	210	TCC CGG GGA GCC AGC	225	ATG
TCC ACT GCG GTC	240	GAA AAC CCA GGC	255	GGC AGG AAA CTC	270	GAC TTT GGA CAG	285	ACA AGC TAT ATT	300	Met
Ser Thr Ala Val	315	Leu Glu Asn Pro Gly	330	Leu Leu Arg Lys	345	Ser Asp Phe Gly Gln	360	Thr Ser Tyr Ile	375	Glu
GAC AAC TGC AAT	390	AAT GGT GCC ATA	405	CTC ATC TTC TCA	420	AAA GAA GAA GTT	435	GCA TTG GCC AAA	450	GTA
Asp Asn Cys Asn	465	Gln Asn Gly Ala Ile	480	Leu Ile Phe Ser	495	Leu Lys Glu Val	510	Ala Leu Ala Lys	525	Val
TTG CGC TTA TTT	540	GAG AAT GAT GTA	555	CTG ACC CAC ATT	570	TCT AGA CCT TCT	585	TTA AAG AAA GAT	600	GAG
Leu Arg Leu Phe	615	Glu Asn Asp Val	630	Leu Thr His Ile	645	GAA Ser Arg Pro Ser	660	Leu Lys Lys Asp	675	Glu
TAT GAA TTT TTC	690	CAT TTG GAT AAA	705	AGC CTG CCT GCT	720	ACA AAC ATC ATC	735	ATC AGG CAT	750	ASP
Tyr Glu Phe Thr	765	His Leu Asp Lys	780	Ser Leu Pro Ala	795	Thr Asn Ile Ile	810	Ile Arg His	825	ASP
ATT GGT GCC ACT	840	CAT GAG CTT TCA	855	GAT AAG AAG AAA	870	ACA ACA GTG CCC	885	CCA AGA ACC ATT	900	CAA
Ile Gly Ala Thr	915	Val His Glu Leu Ser	930	Arg Asp Lys Lys	945	GAC Thr Val Pro Trp	960	Pro Arg Thr Ile	975	Gln
GAG CTG GAC AGA	1000	TTT GCC AAT CAG	1015	AGC TAT GGA GCG	1030	CTG GAT GCT GAC	1045	CCT GGT TTT AAA	1060	GAT
Glu Leu Asp Arg	1085	Phe Ala Asn Gln Ile	1100	Leu Ser Tyr Gly Ala	1115	GAA Glu Asp Ala Asp	1130	Pro Gly Phe Lys	1145	ASP
CCT GTG TAC CGT	1170	GCA Ala Arg Arg Lys	1185	GCT GAC ATT GCC	1200	AAC TAC CGC CAT	1215	CAG CCC ATC CCT	1230	CGA
Pro Val Tyr Arg	1255	AGA Arg Arg Lys Gln	1270	Ala Asp Ile Ala	1285	Tyr Asn Tyr Arg His	1300	Gln Pro Ile Pro	1315	Arg
GTG GAA TAC ATG	1350	GAG GAA AAG AAA	1365	TGG GGC ACA GTG	1380	AAG ACT CTG AAG	1395	TTC TAT AAA ACC	1410	CAT
Val Glu Tyr Met	1440	Glu Glu Lys Lys	1455	Trp Gly Thr Val	1470	Lys Thr Leu Lys	1485	Leu Tyr Lys Thr	1500	His
GCT TGC TAT GAG	1520	TAC AAT CAC ATT	1535	CTT CTT GAA AAG	1550	TGT GGC TTC CAT	1565	GAT AAC ATT CCC	1580	CAG
Ala Cys Tyr Glu	1600	Tyr Asn His Ile Phe	1615	Pro Leu Leu Glu Lys	1630	Tyr Cys Gly Phe His	1645	Asp Asn Ile Pro	1660	Gln

FIG. 13-1

CTG GAA GAC GTT Val 915 TCT CAA TTC CTG CAG 930 TGC ACT GGT TTC CGC CTC CGA CCT GTG 960 GCT GGC CTG CTT TCC 975 TCT
 Leu Glu Asp Val 990 GGT GGC CTG GCC TTC CAG 1005 TGC Cys Thr Gly Phe 1020 ACA CAG TAC ATC AGA 1035 GAT Gly Ala 1050 Ser
 Arg Asp Phe Leu 1065 CCT GAC ATC TGC CAT GAG 1080 GAG CTG TTG GGA CAT TGC CAC 1095 GTG CCC TTG TTT TCA 1110 GAT C6C AGC 1125 CAG
 Tyr Thr Pro Glu 1140 CCT GAC ATC TGC CAT GAG 1155 GAG CTG TTG GGA CAT TGC CAC 1170 GAT C6C AGC 1185 GAT C6C AGC 1200 Gln
 TTT TCC CAG GAA 1215 ATT GGC CTT GCC TCT TGC AAA CAA GGA GAC TCC ATA 1230 CTG GGT GCA CCT GAT GAA 1245 AAG GCA TAT GGT GCT 1260 GGG CTC CTG TCA TCC 1275 Phe
 Phe Ser Gln Glu 1290 TTT GGC CTC TGC AAA CAA GGA GAC TCC ATA 1305 Gln Gly Asp Ser Ile 1320 CCC CTG GAG 1335 AAG ACA GCC ATC CAA AAT 1350 Phe
 GGT GAA TTA CAG 1365 TAC TGC TTA CAG GAG 1380 TAT TAC GTG GCA GAG 1395 AGT TTT AAT GAT GCC 1410 AAG GAG AAA GTA AGG 1425 Asn
 Gly Glu Leu Gln 1395 TAT TAC GTG GCA GAG 1405 TAT Tyr Val Ala Glu 1420 TCA TCC 1435 AAG GAG AAA GTA AGG 1450 Asn
 TAC ACT GTC ACG 1440 ATA CCT CGG CCC TTC TCA GAT 1455 Ser Val Arg Tyr Asp 1470 CCA TAC ACC CAA AGG 1485 ATT GAG GTC TTG GAC 1500 AAT
 Tyr Thr Val Thr 1460 Ile Pro Arg Pro Phe 1475 TCC ATT AAC AGT GAA 1490 ATT GGA ATC CTT TGC 1505 AGT GCC CTC CAG AAA ATA 1520 Ile
 TTT GCT GCC ACA 1490 Ile Pro Arg Pro Phe 1505 TCC ATT AAC AGT GAA 1520 ATT GGA ATC CTT TGC 1535 AGT GCC CTC CAG AAA ATA 1560 Ser
 Phe Ala Ala Thr 1515 TCC GAT GAT TGC AAA CAA GGA 1530 TCC ATT AAC AGT GAA 1545 ATT GGA ATC CTT TGC 1560 AGT GCC CTC CAG AAA ATA 1590 Ile
 ACC CAG CAG CTT AAG ATT TTG GCT GAT TGC AAA CAA GGA 1530 TCC ATT AAC AGT GAA 1545 ATT GGA ATC CTT TGC 1560 AGT GCC CTC CAG AAA ATA 1590 Ile
 Thr Gln Gln Leu 1590 TCC GAT GAT TGC AAA CAA GGA 1530 TCC ATT AAC AGT GAA 1545 ATT GGA ATC CTT TGC 1560 AGT GCC CTC CAG AAA ATA 1590 Ile
 AAG TAA AGC CAT GGA CAG AAT GTG GTC 1605 TGT CAG CTG TGA ATC 1620 TGT TGA TGG AGA TCC 1635 AAC TAT TTC TTT CAT 1650 CAG
 Lys 1665 TGA AAT AAC AGC CTT AAA TCC TTT ACA AGA 1695 TGG AGA AAC AAC AAA 1725 TAA
 AAA AAG TCC GAA 1740 TGA AAT GAC AGG ATA 1830 CAA TTG AGT TAA ATC 1845 AGT AAT CTG TCG CAT 1860 TTC ATC AAG ATT AAT 1875 TAA
 GTC AAA ATA ATC 1815 TGA AAT GAC AGG ATA 1830 CAA TTG AGT TAA ATC 1845 AGT AAT CTG TCG CAT 1860 TTC ATC AAG ATT AAT 1875 TAA
 GAT TTA GAG ATG ATA ATC CCA TAC TCT CAA TTG AGT TAA ATC 1845 AGT AAT CTG TCG CAT 1860 TTC ATC AAG ATT AAT 1875 TAA

FIG. 13-2

AAT TTG GGA CCT	1890	GCT TCA	1905	TTC AAC	1920	TCA TAA	1935	TAA GGC	1950
TAA AAC ACA AGA	1965	CTG TCA	1980	TTA GAA TTG	1995	TAA TAA	2010	TAA GGC	2025
TTT AGT TAA CTA	2040	TGA TTC	2055	CAA TTA CTA	2070	TAA TAA	2085	TAA GGC	2100
AAA TAG TTA CAA	2115	GCA TTG	2130	AAC TTC TTT	2145	TAA TAA	2160	TAA GGC	2175
AAA TAC TGC TGT	2190	ATA AGG	2205	TAA TAA AAC	2220	TAA TAA	2235	TAA GGC	2250
CAA GTC TGT TTT	2265	GGG AAA	2280	CAC TTT GAG	2295	TAA TAA	2310	TAA GGC	2325
TTT AGG AAA TGT	2340	TCA CTG	2355	AAA TAA	2370	TAA TAA	2385	TAA GGC	2400
TTG TAT TAG TAA	2415	TAA AAC	2430	ATT AGT AGT	2445	TAA TAA	2460	TAA GGC	2475

FIG. 13-3




FIG. 14

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.